$9.20
6.03% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US45257U1088
Symbol
IMNM
Sector
Industry

Immunome Inc Stock price

$9.20
+1.29 16.31% 1M
-3.38 26.87% 6M
-1.42 13.37% YTD
-6.84 42.64% 1Y
-4.25 31.60% 5Y
-4.25 31.60% 10Y
-4.25 31.60% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.59 6.03%
ISIN
US45257U1088
Symbol
IMNM
Sector
Industry

Key metrics

Market capitalization $800.51m
Enterprise Value $483.19m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 44.17
P/S ratio (TTM) P/S ratio 73.17
P/B ratio (TTM) P/B ratio 2.60
Revenue growth (TTM) Revenue growth -13.79%
Revenue (TTM) Revenue $10.94m
EBIT (operating result TTM) EBIT $-177.75m
Free Cash Flow (TTM) Free Cash Flow $-178.87m
Cash position $317.32m
EPS (TTM) EPS $-2.58
P/E forward negative
P/S forward 188.54
EV/Sales forward 113.80
Short interest 15.89%
Show more

Is Immunome Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Immunome Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Immunome Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Immunome Inc forecast:

Buy
100%

Financial data from Immunome Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
11 11
14% 14%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 38 38
64% 64%
344%
- Research and Development Expense 151 151
340% 340%
1,381%
-176 -176
299% 299%
-1,606%
- Depreciation and Amortization 2.02 2.02
288% 288%
18%
EBIT (Operating Income) EBIT -178 -178
299% 299%
-1,625%
Net Profit -205 -205
12% 12%
-1,875%

In millions USD.

Don't miss a Thing! We will send you all news about Immunome Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunome Inc Stock News

Neutral
Business Wire
9 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on June 2, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase...
Neutral
Business Wire
23 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome to Present at Upcoming Investor Conferences.
Neutral
Business Wire
about one month ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2025, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase ...
More Immunome Inc News

Company Profile

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Head office United States
CEO Clay Siegall
Employees 118
Founded 2006
Website immunome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today